Chemistry of tumour targeted T1 based MRI contrast agents

Current Topics in Medicinal Chemistry

Volumn 10, Issue 12, 2010, Pages 1158-1183

  Kamaly, Nazila ^a,b   Miller, Andrew D ^b   Bell, Jimmy D ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Gadolinium; MRI; MRI contrast agents; Nanomedicine; Nanoparticles; Paramagnetic contrast agents; T1 contrast agents; Tumour; Tumour targeting

Indexed keywords

DENDRIMER; GADOLINIUM PENTETATE; LIPOSOME; MANGANESE CHLORIDE; MANGANESE OXIDE; METAL ORGANIC FRAMEWORK; MONOCRYSTALLINE IRON OXIDE NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; POLYMER; QUANTUM DOT; SILICON DIOXIDE;

ANGIOGENESIS; ARTICLE; MICELLE; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING;

CHEMISTRY, PHARMACEUTICAL; CONTRAST MEDIA; HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955626463     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610791384199     Document Type: Article

References (144)

1. Dragnev, K.H. In search of the magic bullet. Transl. Res., 2009, 153(6), 261-262.
2. Weissleder, R.; Pittet, M.J. Imaging in the era of molecular oncology. Nature, 2008, 452, 580-589.
3. Mahmood, U.; Josephson, L. Molecular MR imaging probes. P. IEEE, 2005, 93, 800-808.
4. Fass, L. Imaging and cancer: A review. Mol. Oncol., 2008, 2(2), 115-152.
5. Weinmann, H.J.; Ebert, W.; Misselwitz, B.; Schmitt-Willich, H. Tissue-specific MR contrast agents. Eur. J. Radiol., 2003, 46(1), 33-44.
6. Lyons, S. K. Advances in imaging mouse tumour models in vivo. J. Pathol., 2005, 205, 194-205.
7. Hermann, P.; Kotek, J.; Kubicek, V. c.; Lukes, I. Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes. Dalton Trans., 2008, 3027-3047.
8. Geraldes, C.F.; Laurent, S. Classification and basic properties of contrast agents for magnetic resonance imaging. Contrast Media Mol. I., 2009, 4(1), 1-23.
9. Caravan, P.; Ellison, J.J.; McMurry, T.J.; Lauffer, R. B. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem. Rev., 1999, 99(9), 2293-2352.
10. Parac-Vogt, T.N.; Kimpe, K.; Laurent, S.; Pierart, C.; Elst, L. V.; Muller, R.N.; Binnemans, K. Gadolinium DTPA-monoamide complexes incorporated into mixed micelles as possible MRI contrast agents. Eur. J. Inorg. Chem., 2004, 3538-3543.
11. Bottrill, M.; Kwok, L.; Long, N.J. Lanthanides in magnetic resonance imaging. Chem. Soc. Rev., 2006, 35(6), 557-571.
12. Frullano, L.; Meade, T.J., Multimodal MRI contrast agents. J. Biol. Inorg. Chem., 2007, 12(7), 939-949.
13. Fatin-Rouge, N.; Toth, E.; Meuli, R.; Bunzli, J.C. Enhanced imaging properties of a GdIII complex with unusually large relaxivity. J. Alloys Compd., 2004, 374(1-2), 298-302.
14. Lin, S. P.; Brown, J.J. MR contrast agents: Physical and pharmacologic basics. J. Magn. Reson. Imaging, 2007, 25(5), 884-899.
15. 3+ with 1,4,7,10-tetrakis(carboxymethyl)- 1,4,7,10-tetraazacyclododecane(dota)-characterization of three successive complexing phases: study of the thermodynamic and structural properties of the complexes by potentiometry, luminescence-spectroscopy, and EXAFS. Chemistry, 2004, 10(20), 5218-5232.
16. Kuo, P.H.; Kanal, E.; Abu-Alfa, A.K.; Cowper, S.E. Gadoliniumbased MR contrast agents and nephrogenic systemic fibrosis. Radiology, 2007, 242, 647-649.
17. 153Gd-L-LDL as radiotracers for detection of AR4-2J rat pancreatic tumors. Appl. Organomet. Chem., 2004, 18(1), 1-8.
18. Heppeler, A.; Froidevaux, S.; Maecke, H.R.; Jermann, E.; Behe, M.; Powell, P.; Hennig, M. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumourtargeting properties and potential for receptor-mediated internal radiotherapy. Chemistry, 1999, 5(7), 1974-1981.
19. Tekade, R. K.; Kumar, P. V.; Jain, N.K. Dendrimers in oncology: an expanding horizon. Chem. Rev., 2009, 109, 49-87.
20. 1 mapping. Int. J. Nanomed., 2007, 2, 191-200.
21. Comblin, V.; Gilsoul, D.; Hermann, M.; Humblet, V.; Jacques, V.; Mesbahi, M.; Sauvage, C.; Desreux, J.F. Designing new MRI contrast agents: a coordination chemistry challenge. Coordin. Chem. Rev., 1999, 185-186, 451-470.
22. Morcos, S. K. Extracellular gadolinium contrast agents: differences in stability. Eur. J. Radiol., 2008, 66(2), 175-179.
23. Oliver, M.; Ahmad, A.; Kamaly, N.; Perouzel, E.; Caussin, A.; Keller, M.; Herlihy, A.; Bell, J.; Miller, A.D.; Jorgensen, M.R. MAGfect: a novel liposome formulation for MRI labelling and visualization of cells. Org. Biomol. Chem., 2006, 4(18), 3489-3497.
24. De Leon-Rodriguez, L.M.; Kovacs, Z.; Dieckmann, G.R.; Sherry, A.D. Solid- phase synthesis of DOTA-peptides. Chem. Eur. J., 2004, 10(5), 1149-1155.
25. DeNardo, S.J.; DeNardo, G.L.; Yuan, A.; Richman, C.M.; O'Donnell, R.T.; Lara, P.N.; Kukis, D.L.; Natarajan, A.; Lamborn, K.R.; Jacobs, F.; Siantar, C.L H. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: Comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT. Clin. Cancer Res., 2003, 9(10), 3938s-3944s.
26. Brouwers, A. H.; Buijs, W.C.A.M.; Oosterwijk, E.; Boerman, O.C.; Mala, C.; De Mulder, P.H. M.; Corstens, F.H.M.; Mulders, P.F.A.; Oyen, W.J.G. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with I-131 or In-111: An intrapatient comparison. Clin. Cancer Res., 2003, 9(10), 3953s-3960s.
27. Frericks, B.B.; Loddenkemper, C.; Huppertz, A.; Valdeig, S.; Stroux, A.; Seja, M.; Wolf, K.J.; Albrecht, T. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB- DTPA. Am. J. Roentgenol., 2009, 193(4), 1053-1060.
28. Pinker, K.; Grabner, G.; Bogner, W.; Gruber, S.; Szomolanyi, P.; Trattnig, S.; Heinz-Peer, G.; Weber, M.; Fitzal, F.; Pluschnig, U. A combined high temporal and high spatial resolution 3 tesla MR imaging protocol for the assessment of breast lesions: initial results. Invest. Radiol., 2009, 44, 553-558.
29. Godelman, A.; Haramati, L.B. MR imaging in diagnosis and staging of pulmonary carcinoma. Magn. Reson. Imaging C., 2008, 16, 309-318.
30. Egeland, T.A.M.; Simonsen, T.G.; Gaustad, J.V.; Gulliksrud, K.; Ellingsen, C.; Rofstad, E. K. Dynamic contrast-enhanced magnetic resonance imaging of Tumors: preclinical validation of parametric images. Radiat. Res., 2009, 172(3), 339-347.
31. Tuncbilek, N.; Kaplan, M.; Altaner, S. Value of dynamic contrastenhanced MRI and correlation with tumor angiogenesis in bladder Cancer. Am. J. Roentgenol., 2009, 192, 949-955.
32. Sawant, R. M.; Hurley, J.P.; Salmaso, S.; Kale, A.; Tolcheva, E.; Levchenko, T. S.; Torchilin, V.P. SMART drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug. Chem., 2006, 17, 943-949.
33. Crich, S.G.; Cabella, C.; Barge, A.; Belfiore, S.; Ghirelli, C.; Lattuada, L.; Lanzardo, S.; Mortillaro, A.; Tei, L.; Visigalli, M.; Forni, G.; Aime, S. In vitro and in vivo magnetic resonance detection of tumor cells by targeting glutamine transporters with Gd-based probes. J. Med. Chem., 2006, 49(16), 4926-4936.
34. Hovland, R.; Glogard, C.; Aasen, A. J.; Klaveness, J. Gadolinium DO3A derivatives mimicking phospholipids; preparation and in vitro evaluation as pH responsive MRI contrast agents. Perkin 2, 2001, 929-933.
35. Storr, T.; Thompson, K.H.; Orvig, C. Design of targeting ligands in medicinal inorganic chemistry. Chem. Soc. Rev., 2006, 35(6), 534-544.
36. Forsen, S. Hoffman, RA. Study of moderately rapid chemical exchange reactions by means of nuclear magnetic double resonance. J. Chem. Phys. 1963, 39, 2892-2901.
37. Aime, S.; Castelli, D.D.; Terreno, E. Highly sensitive MRI chemical exchange saturation transfer agents using liposomes. Angew Chem., 2005, 44, 5513-5515.
38. Langereis, S.; Dirksen, A.; De Waal, B.F. M.; Van Genderen, M.H.P.; De Lussanet, Q.G.; Hackeng, T.M.; Meijer, E.W. Solidphase synthesis of a cyclic NGR-functionalized Gd(III)DTPA complex. Eur. J. Org. Chem., 2005, 2534-2538.
39. Ye, F.R.; Jeong, E.K.; Jia, Z.J.; Yang, T.X.; Parker, D.; Lu, Z.R. A peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI. Bioconjug. Chem., 2008, 19(12), 2300-2303.
40. Li, G. L.; Slansky, A.; Dobhal, M.P.; Goswami, L.N.; Graham, A.; Chen, Y.H.; Kanter, P.; Alberico, R.A.; Spernyak, J.; Mazurchuk, R.; Oseroff, A.; Grossman, Z.; Pandey, R.K. Chlorophyll-a analogues conjugated with aminobenzyl-DTPA as potential bifunctional agents for magnetic resonance imaging and photodynamic therapy. Bioconjug. Chem., 2005, 16(1), 32-42.
41. Duimstra, J. A.; Femia, F. J.; Meade, T. J. A gadolinium chelate for detection of beta-glucuronidase: a self-immolative approach. J. Am. Chem. Soc., 2005, 127, 12847-12855.
42. Frullano, L.; Rohovec, J.; Aime, S.; Maschmeyer, T.; Prata, M.I.; de Lima, J.J.P.; Geraldes, C.; Peters, J.A. Towards targeted MRI: New MRI contrast agents for sialic acid detection. Chemistry, 2004, 10(20), 5205-5217.
43. De Leon-Rodriguez, L.M.; Lubag, A.J.M.; Malloy, C.R.; Martinez, G.V.; Gillies, R.J.; Sherry, A.D. Responsive MRI agents for sensing metabolism in vivo. Acc. Chem. Res., 2009, 42, 948-957.
44. Park, J.A.; Lee, J.J.; Jung, J.C.; Yu, D.Y.; Oh, C.; Ha, S.; Kim, T.J.; Chang, Y.M. Gd-DOTA conjugate of RGD as a potential tumor-targeting MRI contrast agent. Chembiochem., 2008, 9(17), 2811-2813.
45. Chen, X.Y.; Park, R.; Tohme, M.; Shahinian, A.H.; Bading, J.R.; Conti, P.S. and autoradiographic imaging of breast cancer alpha(v)- integrin expression using F-18- and Cu-64-labeled RGD peptide. Bioconjug. Chem., 2004, 15(1), 41-49.
46. Schmieder, A.H.; Winter, P.M.; Caruthers, S.D.; Harris, T.D.; Williams, T.A.; Allen, J.S.; Lacy, E.K.; Zhang, H.; Scott, M.J.; Hu, G. Molecular MR imaging of melanoma angiogenesis With alpha(v)beta(3)-targeted paramagnetic nanoparticles. Magn. Reson. Med., 2005, 53, 621-627.
47. Sipkins, D.A.; Cheresh, D.A.; Kazemi, M.R.; Nevin, L.M.; Bednarski, M.D.; Li, K.C.P. Detection of tumor angiogenesis in vivo by ava3-targeted magnetic resonance imaging. Nat. Med., 1998, 4(5), 623-626.
48. Janssen, M.L.; Oyen, W.J.; Dijkgraaf, I.; Massuger, L.F.; Frielink, C.; Edwards, D.S.; Rajopadhye, M.; Boonstra, H.; Corstens, F.H.; Boerman, O.C. Tumor targeting with radiolabeled alphavbeta3 integrin binding peptides in a nude mouse model. Cancer Res., 2002, 62(21), 6146-6151.
49. Haubner, R.; Wester, H.J.; Burkhart, F.; Senekowitsch-Schmidtke, R.; Weber, W.; Goodman, S.L.; Kessler, H.; Schwaiger, M. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med., 2001, 42(2), 326-336.
50. Ruoslahti, E. Drug targeting to specific vascular sites. Drug Discov. Today, 2002, 7(22), 1138-1143.
51. 3 expression. Cancer Metast. Rev., 2008, 27(4), 631-644.
52. 3 integrin. Steroids, 2007, 72(2), 165-170.
53. Jastrzebska, B.; Lebel, R.; Therriault, H.; McIntyre, J.O.; Escher, E.; Guerin, B.; Paquette, B.; Neugebauer, W.A.; Lepage, M. New enzyme-activated solubility-switchable contrast agent for magnetic resonance imaging: From synthesis to in Vivo imaging. J. Med. Chem., 2009, 52(6), 1576-1581.
54. Lebel, R.; Jastrzebska, B.; Therriault, H.; Cournoyer, M.M.; McIntyre, J.O.; Escher, E.; Neugebauer, W.; Paquette, B.; Lepage, M. Novel solubility-switchable MRI agent allows the noninvasive detection of matrix metalloproteinase-2 activity In Vivo in a mouse model. Magn. Reson. Med. 2008, 60(5), 1056-1065.
55. Kohrmann, A.; Kammerer, U.; Kapp, M.; Dietl, J.; Anacker, J. U.K., M. Kapp, J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer, 2009, 9(188).
56. Roomi, M.W.; Monterrey, J.C.; Kalinovsky, T.; Rath, M.; Niedzwiecki, A. Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol. Rep., 2009, 21(5), 1323-1333.
57. Turk, B.E.; Huang, L.L.; Piro, E.T.; Cantley, L.C. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nat. Biotechnol., 2001, 19(7), 661-667.
58. Scherer, R.L.; McIntyre, J.O.; Matrisian, L.M. Imaging matrix metalloproteinases in cancer. Cancer Metast. Rev. 2008, 27(4), 679-690.
59. Van de Wiele, C.; Oltenfreiter, R. Imaging probes targeting matrix metalloproteinases. Cancer Biother. Radio, 2006, 21(5), 409-417
60. Pirollo, K.F.; Chang, E.H. Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends Biotechnol., 2008, 26(10), 552-558.
61. Torchilin, V.P. Nanocarriers. Pharm. Res., 2007, 24(12), 2333-2334.
62. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. In: Recent Advances in Drug Delivery Systems; Anderson, J. M., Kim, S. W., Kopecek, J., Robinson, J. R., Eds.; Elsevier: Salt Lake City, UT, 1999; pp. 271-284.
63. Andresen, T.L.; Jensen, S.S.; Jorgensen, K. Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release. Prog. Lipid Res., 2005, 44(1), 68-97.
64. Perrault, S.D.; Walkey, C.; Jennings, T.; Fischer, H.C.; Chan, W.C.W. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett., 2009, 9(5), 1909-1915.
65. Davis, M.E.; Chen, Z.; Shin, D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov., 2008, 7(9), 771-782.
66. Iyer, A.K.; Khaled, G.; Fang, J.; Maeda, H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today, 2006, 11(17-18), 812-818.
67. Atri, M. New technologies and directed agents for applications of cancer imaging. J. Clin. Oncol., 2006, 24(20), 3299-3308.
68. Castelli, D.D.; Terreno, E.; Cabella, L. Chaabane, S. Lanzardo, L. Tei, M. Visigalli, S. Aime. Evidence for in vivo macrophage mediated tumor uptake of paramagnetic/fluorescent liposomes. NMR Biomed., 2009, 22(10), 1084-1092.
69. Tilcock, C.; Unger, E.; Cullis, P.; MacDougall, P. Liposomal Gd-DTPA: preparation and characterization of relaxivity. Radiology, 1989, 171, 77-80.
70. Unger, E., Tilcock, C., Ahkong, Q.F. and Fritz, T. Paramagnetic liposomes as magnetic resonance contrast agents. Invest. Radiol., 1990, 25, S65-S66.
71. Oliver, M.; Ahmad, A.; Kamaly, N.; Perouzel, E.; Caussin, A.; Keller, M.; Herlihy, A.; Bell, J.; Miller, A.D.; Jorgensen, M.R. MAGfect: a novel liposome formulation for MRI labelling and visualization of cells. Org. Biomol. Chem., 2006, 4(18), 3489-3497.
72. Kamaly, N.; Kalber, T.; Ahmad, A.; Oliver, M.H.; So, P.W.; Herlihy, A.H.; Bell, J. D.; Jorgensen, M.R.; Miller, A.D. Bimodal paramagnetic and fluorescent liposomes for cellular and tumor magnetic resonance imaging. Bioconjug. Chem., 2008, 19, 118-129.
73. Evelhoch, J.L.; Gillies, R.J.; Karczmar, G.S.; Koutcher, J.A.; Maxwell, R.J.; Nalcioglu, O.; Raghunand, N.; Ronen, S.M.; Ross, B.D.; Swartz, H.M. Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia, 2000, 2(1/2), 152-165.
74. Chauhan, V.P.; Lanning, R.M.; Diop-Frimpong, B.; Mok, W.; Brown, E.B.; Padera, T.P.; Boucher, Y.; Jain, R.K. Multiscale measurements distinguish cellular and interstitial hindrances to diffusion in vivo. Biophys. J., 2009, 97(1), 330-336.
75. Lindner, L.H.; Reinl, H.M.; Schlemmer, M.; Stahl, R.; Peller, M. Paramagnetic thermosensitive liposomes for MR-thermometry. Int. J. Hyperther., 2005, 21, 575-588.
76. Lokling, K.E.; Skurtveit, R.; Bjornerud, A.; Fossheim, S.L. Novel pH-sensitive paramagnetic liposomes with improved MR properties. Magn. Reson. Med. 2004, 51(4), 688-696.
77. Lokling, K.E.; Fossheim, S.L.; Skurtveit, R.; Bjornerud, A.; Klaveness, J. pH-sensitive paramagnetic liposomes as MRI contrast agents: in vitro feasibility studies. Magn. Reson. Imaging, 2001, 19(5), 731-738.
78. Osinski, M.; Jovin, T.M.; Yamamoto, K. Biomedical applications of colloidal nanocrystals. J. Biomed. Biotechnol., 2007, 2007, 82752.
79. Saito, R.; Bringas, J.R.; McKnight, T.R.; Wendland, M.F.; Mamot, C.; Drummond, D.C.; Kirpotin, D.B.; Park, J.W.; Berger, M.S.; Bankiewicz, K.S., Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res., 2004, 64(7), 2572-2579.
80. Yap, T.A.; Carden, C.P.; Kaye, S.B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat. Rev. Cancer, 2009, 9(3), 167-181.
81. Lutz, J. F.; Stiller, S.; Hoth, A.; Kaufner, L.; Pison, U.; Cartier, R. One-Pot synthesis of PEGylated ultrasmall iron-oxide nanoparticles and their in Vivo evaluation as magnetic resonance imaging contrast agents. Biomacromolecules, 2006, 7, 3132-3138.
82. Lee, H.Y.; Jee, H.W.; Seo, S.M.; Kwak, B.K.; Khang, G.; Cho, S.H. Diethylenetriaminepentaacetic acid-gadolinium (DTPA-Gd)-conjugated polysuccinimide derivatives as magnetic resonance imaging contrast agents. Bioconjug. Chem., 2006, 17, 700-706.
83. Mohs, A.M.; Wang, X.; Goodrich, K.C.; Zong, Y.; Parker, D.L.; Lu, Z.R., PEG-g-poly(GdDTPA-co-L-cystine): A biodegradable macromolecular blood pool contrast Agent for MR imaging. Bioconjug. Chem., 2004, 15(6), 1424-1430.
84. Kobayashi, H.; Kawamoto, S.; Saga, T.; Sato, N.; Ishimori, T.; Konishi, J.; Ono, K.; Togashi, K.; Brechbiel, M. W. Avidindendrimer-(1B4M-Gd)(254): A tumor-targeting therapeutic agent for gadolinium neutron capture therapy of intraperitoneal disseminated tumor which can be monitored by MRI. Bioconjug. Chem., 2001, 12(4), 587-593.
85. Doble, D.M.J.; Botta, M.; Wang, J.; Aime, S.; Barge, A.; Raymond, K.N. Optimization of the relaxivity of MRI contrast agents: effect of poly(ethylene glycol) chains on the waterexchange rates of GdIII complexes. J. Am. Chem. Soc., 2001, 123(43), 10758-10759.
86. Margerum, L.D.; Campion, B.K.; Koo, M.; Shargill, N. Effect of molecular weight on physical and biological properties of macromolecular magnetic resonance imaging contrast agents, Rare earth research. In: Gadolinium(III) DO3A Macrocycles and Polyethylene Glycol Coupled to Dendrimers; Duluth, M.N., Morss, L.R., Eds.; Elsevier Sequoia: Duluth; MN, 1996; pp. 185-190.
87. Chaubet, F.; Bertholon, I.; Serfaty, J.M.; Bazeli, R.; Alsaid, H.; Jandrot-Perrus, M.; Zahir, C.; Even, P.; Bachelet, L.; Touat, Z. A new macromolecular paramagnetic MR contrast agent binds to activated human platelets. Contrast Media Mol. I., 2007, 2(4), 178-188.
88. Aime, S.; Gianolio, E.; Uggeri, F.; Tagliapietra, S.; Barge, A.; Cravotto, G. New paramagnetic supramolecular adducts for MRI applications based on non-covalent interactions between Gd(III)- complexes and β or γ-cyclodextrin units anchored to chitosan. In: International Conference on Biological Inorganic Chemistry; Dawson, J. H., Eds.; Elsevier: Ann Arbor, MI, 2005; pp. 931-938.
89. Mehvar, R. Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J. Control. Release, 2000, 69(1), 1-25.
90. Bogdanov Jr, A.; Matuszewski, L.; Bremer, C.; Petrovsky, A.; Weissleder, R. Oligomerization of paramagnetic substrates result in signal amplification and can be used for MR imaging of molecular targets. Mol. Imaging, 2002, 1(1), 16-23.
91. Helms, B.; Meijer, E.W. Dendrimers at work. Science, 2006, 313(5789), 929.
92. Kobayashi, H.; Kawamoto, S.; Jo, S.K.; Bryant, H.L.; Brechbiel, M.W.; Star, R. A. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug. Chem., 2003, 14(2), 388-394.
93. Weinmann, H.J.; Bauer, H.; Griesinger, C.; Ebert, W.; Misselwitz, B.; Muhler, A.; Schmitt-Willich, H. Early distribution dynamics of polymeric magnetic resonance imaging contrast agents in rats. Acad. Radiol., 2002, 9, S412-S416.
94. Ladd, D.L.; Hollister, R.; Peng, X.; Wei, D.; Wu, G.; Delecki, D.; Snow, R.A.; Toner, J.L.; Kellar, K.; Eck, J. Polymeric gadolinium chelate magnetic resonance imaging contrast agents: design, synthesis, and properties. Bioconjug. Chem., 1999, 10(3), 361-370.
95. Fortina, P.; Kricka, L.J.; Graves, D.J.; Park, J.; Hyslop, T.; Tam, F.; Halas, N.; Surrey, S.; Waldman, S.A., Applications of nanoparticles to diagnostics and therapeutics in colorectal cancer. Trends Biotechnol., 2007, 25(4), 145-152.
96. Bullok, K.E.; Gammon, S.T.; Violini, S.; Prantner, A.M.; Villalobos, V.M.; Sharma, V.; Piwnica-Worms, D. Permeation peptide conjugates for In Vivo molecular imaging applications. Mol. Imaging, 2006, 5, 1-15.
97. Bull, S.R.; Guler, M.O.; Bras, R.E.; Meade, T.J.; Stupp, S.I. Selfassembled peptide amphiphile nanofibers conjugated to MRI contrast agents. Nano Lett., 2005, 5, 1-4.
98. Prantner, A.M.; Sharma, V.; Garbow, J.R.; Piwnica-Worms, D. Synthesis and characterization of a Gd-DOTA-D-permeation peptide for magnetic resonance relaxation enhancement of intracellular targets. Mol. Imaging, 2003, 2, 333-341.
99. Kayyem, J.F.; Kumar, R.; Fraser, S.E.; Meade, T.J. Receptortargeted co-transport of DNA and magnetic resonance contrast agents. Chem. Biol., 1995, 2, 615-620.
100. Koyama, Y.; Talanov, V. S.; Bernardo, M.; Hama, Y.; Regino, C.A.S.; Brechbiel, M.W.; Choyke, P.L.; Kobayashi, H. A dendrimer-based nanosized contrast agent, dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice. J. Magn. Reson. Imaging, 2007, 25(4), 866-871.
101. Barrett, T.; Kobayashi, H.; Brechbiel, M.; Choyke, P.L. Macromolecular MRI contrast agents for imaging tumor angiogenesis. Eur. J. Radiol., 2006, 60(3), 353-366.
102. Cyran, C. C.; Fu, Y.J.; Raatschen, H.J.; Rogut, V.; Chaopathomkul, B.; Shames, D.M.; Wendland, M.F.; Yeh, B.M.; Brasch, R.C. New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues. J. Magn. Reson. Imaging, 2008, 27(3), 581-589.
103. Swanson, S.D.; Kukowska-Latallo, J.F.; Patri, A.K.; Chen, C.; Ge, S.; Cao, Z.; Kotlyar, A.; East, A.T.; Baker, J.R. Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement. Int. J. Nanomed., 2008, 3, 201-210.
104. Vuu, K.; Xie, J.; McDonald, M.A.; Bernardo, M.; Hunter, F.; Zhang, Y.; Li, K.; Bednarski, M.; Guccione, S. Gadoliniumrhodamine nanoparticles for cell labeling and tracking via magnetic resonance and optical imaging. Bioconjug. Chem., 2005, 16, 995-999.
105. Kamaly, N.; Kalber, T.; Thanou, M.; Bell, J. D.; Miller, A.D. Folate receptor targeted bimodal liposomes for tumor magnetic resonance imaging. Bioconjugate Chem., 2009, 20(4), 648-655.
106. Sega, E. I.; Low, P.S. Tumor detection using folate receptor targeted imaging agents. Cancer Metast. Rev., 2008, 27(4), 655-664.
107. Gabizon, A.; Horowitz, A.T.; Goren, D.; Tzemach, D.; Shmeeda, H.; Zalipsky, S. In Vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin. Cancer Res., 2003, 9(17), 6551-6559.
108. Gupta, Y.; Jain, A.; Jain, P.; Jain, S. Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells. J. Drug Target, 2007, 15(3), 231-240.
109. Wu, J.; Liu, Q.; Lee, R.J. A folate receptor-targeted liposomal formulation for paclitaxel. Int. J. Pharm., 2006, 316(1-2), 148-153.
110. Kim, J.S.; Rieter, W.J.; Taylor, K.M.L.; An, H.; Lin, W.L.; Lin, W.B. Self- assembled hybrid nanoparticles for cancer-specific multimodal imaging. J. Am. Chem. Soc., 2007, 129(29), 8962.
111. Konda, S.D.; Aref, M.; Wang, S.; Brechbiel, M.; Wiener, E.C. Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. Magma, 2001, 12(2-3), 104-113.
112. Oyewumi, M.O.; Yokel, R.A.; Jay, M.; Coakley, T.; Mumper, R.J. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumorbearing mice. J. Control. Release, 2004, 95(3), 613-626.
113. Erdogan, S.; Medarova, Z.O.; Roby, A.; Moore, A.; Torchilin, V.P. Enhanced tumor MR imaging with gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes. J. Magn. Reson. Imaging, 2008, 27(3), 574-580.
114. Reulen, S.W.A.; Brusselaars, W.W.T.; Langereis, S.; Mulder, W.J.M.; Breuken, M.; Merkx, M. Protein-liposome conjugates using cysteine-lipids and native chemical ligation. Bioconjug. Chem., 2007, 18, 590-596.
115. Brandwijk, R. J.; Mulder, W.J.M.; Nicolay, K.; Mayo, K. H.; Thijssen, V. L.; Griffioen, A.W. Anginex-conjugated liposomes for targeting of angiogenic endothelial cells. Bioconjug. Chem., 2007, 18, 785-790.
116. Mulder, W.J.M.; Strijkers, G.J.; Griffioen, A.W.; van Bloois, L.; Molema, G.; Storm, G.; Koning, G.A.; Nicolay, K. A Liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug. Chem., 2004, 15(4), 799-806.
117. Vaccaro, M.; Accardo, A.; D'Errico, G.; Schillen, K.; Radulescu, A.; Tesauro, D.; Morelli, G.; Paduano, L. Peptides and Gd complexes containing colloidal assemblies as tumor-specific contrast agents in MRI: Physicochemical characterization. Biophys. J., 2007, 93(5), 1736-1746.
118. 3-integrin targeted multimodal quantum dots. Angiogenesis, 2009, 12(1), 17-24.
119. van Tilborg, G.A.F.; Mulder, W.J.M.; Chin, P.T. K.; Storm, G.; Reutelingsperger, C.P.; Nicolay, K.; Strijkers, G.J. Annexin A5-conjugated quantum dots with a paramagnetic lipidic coating for the multimodal detection of apoptotic cells. Bioconjug. Chem., 2006, 17(4), 865-868.
120. Koole, R.; van Schooneveld, M.M.; Hilhorst, J.; Castermans, K.; Cormode, D.P.; Strijkers, G.J.; Donega, C.D.; Vanmaekelbergh, D.; Griffioen, A.W.; Nicolay, K.; Fayad, Z.A.; Meijerink, A.; Mulder, W.J.M. Paramagnetic lipid-coated silica nanoparticles with a fluorescent quantum dot core: a new contrast agent platform for multimodality imaging. Bioconjug. Chem., 2008, 19(12), 2471-2479.
121. Taylor, K.M.L.; Kim, J.S.; Rieter, W.J.; An, H.; Lin, W.L.; Lin, W.B. Mesoporous silica nanospheres as highly efficient MRI contrast agents. J. Am. Chem. Soc., 2008, 130(7), 2154-2155.
122. Rowe, M.D.; Thamm, D.H.; Kraft, S.L.; Boyes, S.G. Polymermodified gadolinium metal-organic framework nanoparticles used as multifunctional nanomedicines for the targeted imaging and treatment of cancer. Biomacromolecules, 2009, 10(4), 983-993.
123. Eskens, F.A.; Verweij, J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review. Eur. J. Cancer, 2006, 42(18), 3127-3139.
124. Neeman, M.; Gilad, A.A.; Dafni, H.; Cohen, B. Molecular imaging of angiogenesis. J. Magn. Reson. Imaging, 2007, 25(1), 1-12.
125. McDonald, D.M.; Choyke, P.L. Imaging of angiogenesis: from microscope to clinic. Nat. Med., 2003, 9(6), 713-726.
126. Artemov, D.; Mori, N.; Ravi, R.; Bhujwalla, Z.M. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res., 2003, 63(11), 2723-2727.
127. Zhu, W.L.; Mollie, B.; Bhujwalla, Z.M.; Artemov, D. PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approach. Magn. Reson. Med., 2008, 59(4), 679-685.
128. van Tilborg, G.A.F.; Mulder, W.J.M.; van der Schaft, D.W.J.; Reutelingsperger, C.P.M.; Griffioen, A.W.; Strijkers, G.J.; Nicolay, K. Improved magnetic resonance molecular imaging of tumor angiogenesis by avidin-induced clearance of nonbound bimodal liposomes. Neoplasia, 2008, 10(12), 1459-1469.
129. Narula, J.; Kietselaer, B.; Hofstra, L. Role of molecular imaging in defining and denying death. J. Nucl. Cardiology, 2004, 11(3), 349-357.
130. Neves, A.A.; Krishnan, A.S.; Kettunen, M.I.; Hu, D.E.; de Backer, M.M.; Davletov, B.; Brindle, K.M. A paramagnetic nanoprobe to detect tumor cell death using magnetic resonance imaging. Nano Lett., 2007, 7(5), 1419-1423.
131. Krishnan, A.S.; Neves, A.A.; de Backer, M.M.; Hu, D.E.; Davletov, B.; Kettunen, M.I.; Brindle, K.M. Detection of cell death in tumors by using MR imaging and a gadolinium-based targeted contrast agent. Radiology, 2008, 246, 854-862.
132. Crich, S.G.; Lanzardo, S.; Alberti, D.; Belfiore, S.; Ciampa, A.; Giovenzanaz, G. B.; Lovazzano, C.; Pagliarin, R.; Aime, S. Magnetic resonance imaging detection of tumor cells by targeting low-density lipoprotein receptors with Gd-loaded low- density lipoprotein particles. Neoplasia, 2007, 9(12), 1046-1056.
133. Hueber, M.M.; Staubli, A. B.; Kustedjo, K.; Gray, M.H.B.; Shih, J.; Fraser, S.E.; Jacobs, R.E.; Meade, T.J. Fluorescently detectable magnetic resonance imaging agents. Bioconjug. Chem., 1998, 9(2), 242-249.
134. Brekke, C.; Morgan, S.C.; Lowe, A.S.; Meade, T.J.; Price, J.; Williams, S.C.; Modo, M. The in vitro effects of a bimodal contrast agent on cellular functions and relaxometry. NMR Biomed., 2007, 20(2), 77-89.
135. Toth, E.; Helm, L.; Kellar, K.E.; Merbach, A. E. Gd(DTPAbisamide) alkyl copolymers: A hint for the formation of MRI contrast agents with very high relaxivity. Chem. Eur. J., 1999, 5(4), 1202-1211.
136. Zarabi, B.; Borgman, M.P.; Zhuo, J.C.; Gullapalli, R.; Ghandehari, H. Noninvasive monitoring of HPMA copolymer-RGDfK conjugates by magnetic resonance imaging. Pharm. Res., 2009, 26(5), 1121-1129.
137. Strijkers, G.J.; Mulder, W.J.M.; van Tilborg, G.A.F.; Nicolay, K. MRI contrast agents: current status and future perspectives. Anticancer Agents Med. Chem., 2007, 7, 291-306.
138. Skjold, A.; Kristoffersen, A.; Vangberg, T.R.; Haraldseth, O.; Jynge, P.; Larsson, H.B. An apparent unidirectional influx constant for manganese as a measure of myocardial calcium channel activity. J. Magn. Reson. Imaging, 2006, 24(5), 1047-1055.
139. Aoki, I.; Takahashi, Y.; Chuang, K.H.; Silva, A.C.; Igarashi, T.; Tanaka, C.; Childs, R.W.; Koretsky, A.P. Cell labeling for magnetic resonance imaging with the T1 agent manganese chloride. NMR Biomed., 2006, 19(1), 50-59.
140. Van Meir, V.; Pavlova, D.; Verhoye, M.; Pinxten, R.; Balthazart, J.; Eens, M.; Van der Linden, A. In vivo MR imaging of the seasonal volumetric and functional plasticity of song control nuclei in relation to song output in a female songbird. Neuroimage, 2006, 31(3), 981-992.
141. Van Der Linden, A.; Meir, V.V.; Tindemans, I.; Verhoye, M.; Balthazart, J. Applications of manganese-enhanced magnetic resonance imaging (MEMRI) to image brain plasticity in songbirds. NMR Biomed., 2004, 17(8), 602-612.
142. Parkinson, J.R.C.; Chaudhri, O.B.; Bell, J.D. Imaging appetiteregulating Pathways in the central nervous system using manganese-enhanced magnetic resonance imaging. Neuroendocrinology, 2009, 89(2), 121-130.
143. Taylor, K.M.L.; Rieter, W.J.; Lin, W.B. Manganese-based nanoscale metal-organic frameworks for magnetic resonance imaging. J. Am. Chem. Soc., 2008, 130(44), 14358-14359
144. Idee, J.M.; Port, M.; Robic, C.; Medina, C.; Sabatou, M.; Corot, C. Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J. Magn. Reson. Imaging, 2009, 30(6), 1249-58.